Patents by Inventor David Sidransky

David Sidransky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7319023
    Abstract: An assay for detection of a mammalian cell proliferative disorder associated with a hypermutable nucleic acid sequences is provided. The identification of particular hypermutable sequences such as microsatellite loci correlates with a particular cancer, thereby allowing detection of both primary tumors and metastatic sites within a patient.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: January 15, 2008
    Assignee: The Johns Hopkins University
    Inventor: David Sidransky
  • Patent number: 7279312
    Abstract: Methods for detection of a cell proliferative disorder, such as cancer, are provided utilizing analysis of target mutant nucleic acids in saliva specimens. The presence of the target mutant nucleic acids is indicative of a neoplastic disorder of the lung or the head and neck.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: October 9, 2007
    Assignee: The Johns Hopkins University School of Medicine
    Inventor: David Sidransky
  • Publication number: 20070218511
    Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell, and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.
    Type: Application
    Filed: August 14, 2006
    Publication date: September 20, 2007
    Inventors: Jin Jen, Gary Beaudry, Stephen Madden, Arthur Bertlesen, David Sidransky
  • Patent number: 7252935
    Abstract: The present invention provides methods and kits useful for detecting neplasia by measuring the methylation level of biomarkers, especially the promoter region of GSTP1 for the detection of prostate adenocarcinoma.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: August 7, 2007
    Assignee: The John Hopkins University School of Medicine
    Inventor: David Sidransky
  • Publication number: 20050196773
    Abstract: Cancer screening models based on analysis of mass spectroscopy data can be used to predict upper aerodigestive tract cancer, including lung and head and neck cancers. Models can be generated by comparing spectral weight values obtained from upper aerodigestive tract cancer patients and from patients at high risk for such cancer. Predictor or covariate values identify spectral weight values associated with upper aerodigestive tract cancer.
    Type: Application
    Filed: November 12, 2004
    Publication date: September 8, 2005
    Inventors: David Sidransky, Li Mao, Hening Ren
  • Publication number: 20050136403
    Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.
    Type: Application
    Filed: August 16, 2002
    Publication date: June 23, 2005
    Inventors: Mariana Nacht, Tatiana Dracheva, David Sidransky, Stephen Madden, Jin Jen
  • Publication number: 20050095621
    Abstract: The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA.
    Type: Application
    Filed: August 13, 2004
    Publication date: May 5, 2005
    Applicant: The Johns Hopkins University School of Medical
    Inventor: David Sidransky
  • Publication number: 20050048533
    Abstract: The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)?adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer. Moreover, BRAF mutation reliably predicts a poor prognosis for papillary thyroid carcinomas.
    Type: Application
    Filed: April 9, 2004
    Publication date: March 3, 2005
    Applicant: The Johns Hopkins University
    Inventors: David Sidransky, Yoram Cohen, Ming Zhao
  • Publication number: 20050009040
    Abstract: Methods for detection of a cell proliferative disorder, such as cancer, are provided utilizing analysis of target mutant nucleic acids in saliva specimens are described. The presence of target mutant nucleic acids is indicative of a neoplastic disorder of the lung or the head and neck.
    Type: Application
    Filed: January 9, 2004
    Publication date: January 13, 2005
    Inventor: David Sidransky
  • Publication number: 20040171567
    Abstract: Methylation of p16 DNA and a resultant decrease in p16 gene expression is associated with transcriptional block and is associated with a variety of neoplasms. A method for detecting a neoplasm in a subject by doming methylation of 5′CpG islands in p16 DNA, or detecting p16 mRNA or polypeptide levels in a sample is also provided.
    Type: Application
    Filed: September 9, 2003
    Publication date: September 2, 2004
    Applicant: THE JOHNS HOPKINS SCHOOL OF MEDICINE
    Inventors: David Sidransky, Stephen B. Baylin
  • Patent number: 6780592
    Abstract: The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: August 24, 2004
    Assignee: Johns Hopkins University School of Medicine
    Inventor: David Sidransky
  • Publication number: 20040081976
    Abstract: Methods of genomic screening to identify epigenetically silenced genes, including epigenetically silenced tumor suppressor genes are provided. Also provided are methods of detecting a cancer, for example, an esophageal squamous cell carcinoma or a head and neck squamous cell carcinoma, as are methods of treating a subject having such a cancer.
    Type: Application
    Filed: March 7, 2003
    Publication date: April 29, 2004
    Inventor: David Sidransky
  • Publication number: 20040018538
    Abstract: Mitochondrial mutations occur as a product of contact of a person with an environmental pollutant. Mitochondrial mutations are readily detectable in body fluids. Measurement of mitochondrial mutations in body fluids can be used as a dosimeter to monitor exposure to the environmental pollutant. Mitochondrial mutations can also be detected in cancer patients. Probes and primers containing mutant mitochondrial sequences can be used to monitor patient condition.
    Type: Application
    Filed: June 24, 2003
    Publication date: January 29, 2004
    Applicant: Johns Hopkins University
    Inventors: Makiko Fliss, David Sidransky, Jin Jen, Kornelia Polyak, Bert Vogelstein, Kenneth W. Kinzler
  • Patent number: 6605433
    Abstract: Mitochondrial mutations occur as a product of contact of a person with an environmental pollutant. Mitochondrial mutations are readily detectable in body fluids. Measurement of mitochondrial mutations in body fluids can be used as a dosimeter to monitor exposure to the environmental pollutant. Mitochondrial mutations can also be detected in cancer patients. Probes and primers containing mutant mitochondrial sequences can be used to monitor patient condition.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: August 12, 2003
    Assignee: The Johns Hopkins University
    Inventors: Makiko Fliss, David Sidransky, Jin Jen, Komelia Polyak, Bert Vogelstein, Kenneth W. Kinzler
  • Publication number: 20030134309
    Abstract: An assay for detection of a mammalian cell proliferative disorder associated with a hypermutable nucleic acid sequences is provided. The identification of particular hypermutable sequences such as microsatellite loci correlates with a particular cancer, thereby allowing detection of both primary tumors and metastatic sites within a patient.
    Type: Application
    Filed: November 8, 2002
    Publication date: July 17, 2003
    Applicant: The Johns Hopkins University
    Inventor: David Sidransky
  • Publication number: 20030124600
    Abstract: The present invention provides methods and kits useful for detecting neplasia by measuring the methylation level of biomarkers, especially the promoter region of GSTP1 for the detection of prostate adenocarcinoma.
    Type: Application
    Filed: November 15, 2002
    Publication date: July 3, 2003
    Inventor: David Sidransky
  • Publication number: 20030113774
    Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.
    Type: Application
    Filed: October 22, 2002
    Publication date: June 19, 2003
    Applicant: The Johns Hopkins University
    Inventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
  • Publication number: 20030064371
    Abstract: The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA.
    Type: Application
    Filed: September 10, 2001
    Publication date: April 3, 2003
    Inventor: David Sidransky
  • Publication number: 20020197608
    Abstract: Methods for detection of a cell proliferative disorder, such as cancer, are provided utilizing analysis of target mutant nucleic acids in saliva specimens are described. The presence of target mutant nucleic acids is indicative of a neoplastic disorder of the lung or the head and neck.
    Type: Application
    Filed: May 22, 2001
    Publication date: December 26, 2002
    Applicant: Johns Hopkins University School of Medicine
    Inventor: David Sidransky
  • Patent number: 6479234
    Abstract: An assay for detection of a mammalian cell proliferative disorder associated with a hypermutable nucleic acid sequences is provided. The identification of particular hypermutable sequences such as microsatellite loci correlates with a particular cancer, thereby allowing detection of both primary tumors and metastatic sites within a patient.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: November 12, 2002
    Assignee: The Johns Hopkins University
    Inventor: David Sidransky